NCT04579679 2025-07-25
Open-Label Surufatinib in European Patients With NET
Hutchmed
Phase 2 Terminated
Clinical Trials
12 trialsNCT03466216 2025-06-10
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET
Orano Med LLC
Phase 1 Terminated
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04893759 2025-04-17
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Ascentage Pharma Group Inc.
Phase 1 Terminated
NCT02464007 2025-02-25
Study of rSIFN-co for Patients With Advanced Solid Tumors
Sichuan Huiyang Life Science and Technology Corporation
Phase 1 Terminated
NCT05922579 2024-02-29
A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET
Ipsen
Terminated
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT02592707 2023-07-19
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Ipsen
Phase 1/2 Terminated
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02788578 2018-12-21
PRELUDE
Ipsen
Terminated
NCT01374451 2016-12-20
COOPERATE-2
Novartis
Phase 2 Terminated
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated